Anti Rh D Immunoglobulin (300mcg) is a sterile, concentrated solution of purified immunoglobulin G (IgG) fraction containing antibodies against the Rh D antigen, derived from human plasma of screened donors. It is used for the prevention of Rh D alloimmunization (Rh sensitization) in Rh D-negative individuals exposed to Rh D-positive red blood cells. The 300mcg dose is a standard prophylactic dose designed to neutralize approximately 15 mL of Rh D-positive red blood cells (or 30 mL of whole blood).
Adult: Standard prophylactic dose: 300 mcg (approximately 1500 IU) intramuscularly. Dose must be given within 72 hours of a sensitizing event (delivery, abortion, procedure). For antenatal prophylaxis: A single 300 mcg dose at 28-30 weeks gestation.
Note: For intramuscular use only (unless specified as IV on the label). Administer by deep intramuscular injection into the deltoid or anterolateral aspect of the upper thigh. Do not inject intravenously. Do not inject into gluteal region routinely due to risk of sciatic nerve injury. The vial should be at room temperature before use. Inspect for particulate matter or discoloration before administration.
Anti Rh D Immunoglobulin contains high titers of antibodies specific to the Rh D antigen present on the surface of Rh D-positive red blood cells (RBCs). Upon administration to an Rh D-negative individual, these antibodies bind to any circulating Rh D-positive fetal RBCs that have entered the maternal circulation. This binding marks the fetal RBCs for rapid destruction by the reticuloendothelial system (primarily in the spleen) before the mother's immune system can recognize the Rh D antigen and mount a primary, active immune response involving B-cell activation and memory cell formation.
Pregnancy: US FDA Category C. It is extensively used during pregnancy for antenatal prophylaxis (at 28-30 weeks) and post-sensitizing events. Benefits far outweigh risks. It does not cross the placenta in significant amounts to affect the current Rh D-positive fetus.
Driving: Unlikely to affect driving ability. Patients should be advised regarding potential dizziness or malaise.
| Live Attenuated Vaccines (e.g., MMR, Varicella, Yellow Fever) | Anti Rh D Immunoglobulin may interfere with the immune response to live viral vaccines. Antibodies may neutralize the vaccine virus, reducing efficacy. | Major |
Same composition (Anti Rh D Immunoglobulin (300mcg)), different brands: